Nguyen D Khoa, Montesinos M Carmen, Williams Adrienne J, Kelly Maureen, Cronstein Bruce N
Division of Clinical Pharmacology, Department of Medicine, New York University School of Medicine, New York, NY 10016, USA.
J Immunol. 2003 Oct 15;171(8):3991-8. doi: 10.4049/jimmunol.171.8.3991.
We and others have shown that adenosine, acting at its receptors, is a potent modulator of inflammation and angiogenesis. To better understand the regulation of adenosine receptors during these processes we studied the effects of IL-1, TNF-alpha, and IFN-gamma on expression and function of adenosine receptors and select members of their coupling G proteins in human dermal microvascular endothelial cells (HMVEC). HMVEC expressed message and protein for A(2A) and A(2B), but not A(1) or A(3) receptors. IL-1 and TNF-alpha treatment increased message and protein expression of A(2A) and A(2B) receptor. IFN-gamma treatment also increased the expression of A(2B) receptors, but decreased expression of A(2A) receptors. Resting HMVEC and IFN-gamma-treated cells showed minimal cAMP response to the selective A(2A) receptor agonist 2-[2-(4-chlorophenyl)ethoxy]adenosine (MRE0094). In contrast, MRE0094 stimulated a dose-dependent increase in cAMP levels in TNF-alpha-treated cells that was almost completely blocked by the A(2A) receptor antagonist ZM-241385 (4-[2-[7-amino-2-(2-furyl)[1,2,4]triazolo-[2,3-a][1,3,5]triazin-5-ylamino]ethyl]phenol). The nonselective adenosine receptor agonist 5'-(N-ethylcarboxamido)adenosine increased cAMP levels in both TNF-alpha- and IFN-gamma-treated cells, but not control cells, and its effect was only partially reversed by ZM-241385 in TNF-alpha-treated cells and not affected in IFN-gamma-treated cells. HMVEC expressed a higher level of G protein beta1 isoform than beta4 isoform. Although none of the cytokines tested affected G(beta1) expression, both IL-1 and TNF-alpha significantly up-regulated G(beta4) expression. These findings indicate that inflammatory cytokines modulate adenosine receptor expression and function on HMVECs and suggest that the interaction between proinflammatory cytokines and adenosine receptors may affect therapeutic responses to anti-inflammatory drugs that act via adenosine-dependent mechanisms.
我们及其他研究人员已表明,腺苷作用于其受体时,是炎症和血管生成的强效调节剂。为了更好地理解这些过程中腺苷受体的调控机制,我们研究了白细胞介素-1(IL-1)、肿瘤坏死因子-α(TNF-α)和干扰素-γ(IFN-γ)对人真皮微血管内皮细胞(HMVEC)中腺苷受体的表达和功能以及其偶联G蛋白的某些成员的影响。HMVEC表达A(2A)和A(2B)的信使核糖核酸及蛋白,但不表达A(1)或A(3)受体。IL-1和TNF-α处理增加了A(2A)和A(2B)受体的信使核糖核酸及蛋白表达。IFN-γ处理也增加了A(2B)受体的表达,但降低了A(2A)受体的表达。静息的HMVEC和经IFN-γ处理的细胞对选择性A(2A)受体激动剂2-[2-(4-氯苯基)乙氧基]腺苷(MRE0094)显示出最小的环磷酸腺苷(cAMP)反应。相比之下,MRE0094在经TNF-α处理的细胞中刺激cAMP水平呈剂量依赖性增加,这几乎完全被A(2A)受体拮抗剂ZM-241385(4-[2-[7-氨基-2-(2-呋喃基)[1,2,4]三唑并-[2,3-a][1,3,5]三嗪-5-基氨基]乙基]苯酚)阻断。非选择性腺苷受体激动剂5'-(N-乙基甲酰胺基)腺苷在经TNF-α和IFN-γ处理的细胞中均增加了cAMP水平,但在对照细胞中未增加,并且其作用在经TNF-α处理的细胞中仅部分被ZM-241385逆转,而在经IFN-γ处理的细胞中不受影响。HMVEC表达的G蛋白β1亚型水平高于β4亚型。尽管所测试的细胞因子均未影响G(β1)的表达,但IL-1和TNF-α均显著上调了G(β4)的表达。这些发现表明,炎性细胞因子调节HMVEC上腺苷受体的表达和功能,并提示促炎细胞因子与腺苷受体之间的相互作用可能会影响对通过腺苷依赖性机制起作用的抗炎药物的治疗反应。